SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification
SciSparc Ltd. (Nasdaq: SPRC), a clinical-stage pharmaceutical company focused on central nervous system disorders and rare diseases, has successfully regained compliance with Nasdaq's minimum bid price requirement. The company received official notification from Nasdaq on July 18, 2025, confirming that its shares maintained a closing bid price of $1.00 or higher for 10 consecutive business days, satisfying Listing Rule 5550(a)(2).
With this achievement, Nasdaq has closed the previous bid price deficiency matter, marking an important milestone for SciSparc's continued listing on the exchange.
SciSparc Ltd. (Nasdaq: SPRC), una società farmaceutica in fase clinica focalizzata sui disturbi del sistema nervoso centrale e sulle malattie rare, ha riconquistato con successo la conformità al requisito minimo del prezzo di offerta di Nasdaq. La società ha ricevuto la notifica ufficiale da Nasdaq il 18 luglio 2025, confermando che le sue azioni hanno mantenuto un prezzo di chiusura di offerta di almeno $1,00 per 10 giorni lavorativi consecutivi, soddisfacendo la Regola di Quotazione 5550(a)(2).
Con questo risultato, Nasdaq ha chiuso la questione relativa alla precedente carenza del prezzo di offerta, segnando un traguardo importante per la continuazione della quotazione di SciSparc sull’exchange.
SciSparc Ltd. (Nasdaq: SPRC), una compañía farmacéutica en etapa clínica enfocada en trastornos del sistema nervioso central y enfermedades raras, ha recuperado con éxito el cumplimiento del requisito mínimo del precio de oferta de Nasdaq. La empresa recibió una notificación oficial de Nasdaq el 18 de julio de 2025, confirmando que sus acciones mantuvieron un precio de cierre de oferta de $1.00 o más durante 10 días hábiles consecutivos, cumpliendo con la Regla de Listado 5550(a)(2).
Con este logro, Nasdaq ha cerrado el asunto previo relacionado con la deficiencia en el precio de oferta, marcando un hito importante para la continuidad de la cotización de SciSparc en la bolsa.
SciSparc Ltd. (Nasdaq: SPRC)는 중추신경계 질환 및 희귀질환에 집중하는 임상 단계 제약회사로, 나스닥의 최소 입찰 가격 요건을 성공적으로 충족하였습니다. 회사는 2025년 7월 18일 나스닥으로부터 공식 통지를 받았으며, 주식이 10거래일 연속으로 $1.00 이상 종가를 유지하여 상장 규칙 5550(a)(2)를 충족했음을 확인받았습니다.
이번 성과로 나스닥은 이전 입찰 가격 부족 문제를 종결하였으며, SciSparc의 거래소 상장 지속에 중요한 이정표가 되었습니다.
SciSparc Ltd. (Nasdaq : SPRC), une société pharmaceutique en phase clinique spécialisée dans les troubles du système nerveux central et les maladies rares, a réussi à se conformer à nouveau à l'exigence minimale du prix d'offre de Nasdaq. La société a reçu une notification officielle de Nasdaq le 18 juillet 2025, confirmant que ses actions ont maintenu un prix de clôture d'offre de 1,00 $ ou plus pendant 10 jours ouvrables consécutifs, satisfaisant ainsi à la règle de cotation 5550(a)(2).
Grâce à cette réussite, Nasdaq a clos le dossier relatif à la précédente insuffisance du prix d'offre, marquant une étape importante pour la poursuite de la cotation de SciSparc sur la bourse.
SciSparc Ltd. (Nasdaq: SPRC), ein biopharmazeutisches Unternehmen in der klinischen Phase mit Schwerpunkt auf Erkrankungen des zentralen Nervensystems und seltenen Krankheiten, hat die Einhaltung der Mindestgebotspreisanforderung der Nasdaq erfolgreich wiedererlangt. Das Unternehmen erhielt am 18. Juli 2025 eine offizielle Benachrichtigung von der Nasdaq, die bestätigte, dass die Aktien an 10 aufeinanderfolgenden Handelstagen einen Schlussgebotspreis von mindestens $1,00 gehalten haben und somit die Notierungsregel 5550(a)(2) erfüllt ist.
Mit diesem Erfolg hat Nasdaq die vorherige Problematik bezüglich des Gebotspreises abgeschlossen, was einen wichtigen Meilenstein für die weitere Notierung von SciSparc an der Börse darstellt.
- Regained Nasdaq listing compliance, removing delisting risk
- Maintained share price above $1.00 for 10 consecutive trading days
- Resolved previous bid price deficiency matter with Nasdaq
- Previous trading below minimum bid price requirement indicates historical stock price weakness
Tel Aviv, July 22, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (“SciSparc” or the “Company”) (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, reported the receipt on July 18, 2025 of a written notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company has regained compliance with Listing Rule 5550(a)(2), which requires the Company’s ordinary shares to maintain a minimum bid price of
The Nasdaq staff made this determination of compliance after the closing bid price of the Company’s ordinary shares was at
About SciSparc Ltd. (Nasdaq: SPRC):
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer's disease and agitation; and SCI-210 for the treatment of autism and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seeds’ oil-based products on the Amazon.com Marketplace.
Investor Contact:
IR@scisparc.com
Tel: +972-3-6167055
FAQ
Has SciSparc (SPRC) regained Nasdaq compliance in 2025?
What is the minimum bid price requirement for Nasdaq listing that SPRC had to meet?
What does SciSparc's Nasdaq compliance mean for investors?
What is SciSparc's main business focus?
